Stoffels Sets Out Strategy To Save Galapagos
Focus On Phase I/II Licensing Rather Than Late-Stage Prospects
Executive Summary
Pharma veteran Paul Stoffels, the new CEO of Galapagos, is not thinking about using the Belgian biotech’s cash pile to buy Phase III drugs but is open to licensing deals with US firms who have drugs approved at home and are looking for a European partner.
You may also be interested in...
Galapagos Enters Cancer Field With CellPoint Buy
Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.
Galapagos Pledges More Restraint On Pipeline Potential
The Belgium-headquartered firm has struggled of late to impress investors, most recently with data from its salt-inducible kinase inhibitors, and CMO Walid Abi-Saab told Scrip that one reason could be "the level of optimism that prevails in the company. We jump on things a bit ahead of time."